Skip to NavigationSkip to content

Theravance Biopharma

Theravance seals potential $1bn deal with J&J

The JAK inhibitor field is beginning to heat up – AbbVie is soon to enter Phase 3 with its predicted best-in-class therapy, Gilead is working with Galapagos on a potential rival and Celgene started the year off with a $1.1 billion upfront deal for Impact Biomedicine, gaining them access to its JAK2 inhibitor.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches